Dr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)

Aachen (ots) - Grünenthal announced today that Philip Just Larsen
has been appointed Chief Scientific Officer (CSO) and Member of the
Corporate Executive Board. He will assume leadership of Grünenthal's
research and development organization on 1 July 2018. Currently,
Philip holds the role of Global Head of Diabetes Research and
Translational Medicine and Chief Scientific Officer at Sanofi's
German Hub in Frankfurt.

Philip is a senior leader with extensive experience in drug
discovery and development including successful transition into the
clinic. He is a Medical Doctor trained in internal medicine and
neurology, has been awarded a PhD in Neuroscience/Endocrinology and
held international management positions in research and development
at Eli Lilly and Novo Nordisk. Some of the key highlights of his
career include the foundation and leadership of Rheoscience A/S, a
biopharmaceutical company, as well as personal involvement in the
development of three breakthrough medicines - Victoza®/Saxenda®,
Lyxumia®, and Trulicity®.

Philip is a Danish national and a truly international executive
with work experience in his home country, the United States, the
United Kingdom and Germany. He speaks Danish, English and German, is
married and has two children.

"Philip Just Larsen will enrich Grünenthal with his outstanding
scientific curiosity, his experience in leading discovery and
development groups and his willingness to foster collaboration within
and outside of our R&D organization. Throughout his career he brought
life-changing medicines to patients," Gabriel Baertschi, CEO
Grünenthal, said. "We are delighted to welcome Philip as new member
of the Corporate Executive Board, as we gain a passionate leader who
will make every effort to push our organization forward and secure
our long-term success," Dr. Wilhelm Moll, Chairman of the Supervisory
Board Grünenthal, added.

"I am very much looking forward to joining Grünenthal. The company
is committed to research and development and bringing innovation to
patients. As an MD PhD with clinical neurology expertise, I have
first-hand experience in pain management, the core competence at
Grünenthal. I am thrilled to contribute to the development of
innovative medicines for high unmet medical needs in pain," Philip
Just Larsen said.

About Grünenthal

Grünenthal is an entrepreneurial, science-based pharmaceutical
company specialized in pain, gout and inflammation. Our ambition is
to deliver four to five new products to patients in diseases with
high unmet medical need by 2022 and become a EUR2 bn company. We are
a fully integrated research & development company with a long track
record of bringing innovative pain treatments and state-of-the-art
technologies to patients. By sustainably investing in our R&D above
the industrial average, we are strongly committed to innovation.

Grünenthal is an independent, family-owned company headquartered
in Aachen, Germany. We are present in 32 countries with affiliates in
Europe, Latin America and the US. Our products are sold in more than
155 countries and approx. 5,200 employees are working for Grünenthal
worldwide. In 2017, Grünenthal achieved revenues of approx. EUR1.3
bn.

More information: www.grunenthal.com

Follow us on LinkedIn "Grunenthal Group".

For further information, please contact:
Stepan Kracala, Head Global Communications
Tel.: +49 241 569-1335, Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Original-Content von: Grünenthal Group, übermittelt durch news aktuell